Education
About Us
Working with TipRanks
Follow Us
Acarix AB (SE:ACARIX)
:ACARIX
ACARIX Stock Chart & Stats
kr0.28
>-kr0.01(-3.04%)
At close: 4:00 PM EST
kr0.28
>-kr0.01(-3.04%)
Day’s Range― - ―
52-Week Rangekr0.19 - kr0.47
Previous CloseN/A
Volume265.37K
Average Volume (3M)1.57M
Market Cap
kr336.43M
Enterprise Valuekr319.85M
Total Cash (Recent Filing)kr18.27M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta-0.49
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding1,123,320,200
10 Day Avg. Volume1,780,482
30 Day Avg. Volume1,572,056
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)7.91
Price to Sales (P/S)41.02
P/FCF Ratio-6.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Positive Gross Margins & Revenue GrowthPositive gross profit shows CADScor has viable unit economics at the device/consumable level. With revenue growth from a small base, product-level margins provide a structural lever: scaling installed devices and test volumes can improve company profitability as adoption broadens over the medium term.
Low Financial LeverageMinimal debt materially reduces fixed financing obligations and bankruptcy risk. Structurally, low leverage gives management flexibility to raise targeted capital, pursue partnerships or invest in commercial rollouts without heavy interest burden, supporting a steadier multi-month execution path.
Installed-base Consumable Revenue ModelAn installed-base model with single‑use consumables converts capital sales into recurring revenue per device. This structural revenue stream can improve predictability and margins as installed devices and repeat testing grow, aligning incentives for retention and offering a path to durable revenue expansion.
Bears Say
Large Operating Losses Vs RevenueA structural mismatch exists between a high cost base and current sales: 2025 EBIT (~-48M) versus revenue (~7.4M) implies the business is far from break‑even. Persistently large operating losses require significant scale or cost reduction to achieve sustainable profitability, increasing reliance on external capital.
Sharp Equity And Asset ErosionSteady erosion of equity and shrinking assets reflect cumulative losses that weaken the company’s capital base. This reduces the buffer against operational shocks, limits internal funding capacity for commercial expansion, and can impair negotiating leverage with partners and lenders over time.
Consistent Negative Operating And Free Cash FlowSustained negative OCF and FCF mean the business cannot self‑fund growth and must access external financing. Recurring cash burn raises dilution or higher financing cost risk, constrains the pace of commercialization and reimbursement efforts, and extends time required to reach self‑sustaining operations.
Acarix AB News
ACARIX FAQ
What was Acarix AB’s price range in the past 12 months?
Acarix AB lowest stock price was kr0.19 and its highest was kr0.47 in the past 12 months.
What is Acarix AB’s market cap?
Acarix AB’s market cap is kr336.43M.
When is Acarix AB’s upcoming earnings report date?
Acarix AB’s upcoming earnings report date is May 20, 2026 which is in 88 days.
How were Acarix AB’s earnings last quarter?
Acarix AB released its earnings results on Feb 12, 2026. The company reported -kr0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.01.
Is Acarix AB overvalued?
According to Wall Street analysts Acarix AB’s price is currently Overvalued.
Does Acarix AB pay dividends?
Acarix AB does not currently pay dividends.
What is Acarix AB’s EPS estimate?
Acarix AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Acarix AB have?
Acarix AB has 1,123,320,200 shares outstanding.
What happened to Acarix AB’s price movement after its last earnings report?
Acarix AB reported an EPS of -kr0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.649%.
Which hedge fund is a major shareholder of Acarix AB?
Currently, no hedge funds are holding shares in SE:ACARIX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Acarix AB
Acarix AB (publ), a medical technology company, develops and commercializes diagnostic tests for cardiovascular diseases in Germany, Sweden, the Middle East, Switzerland, Austria, and internationally. The company offers CADScor System, a non-invasive and ultra-sensitive analytical device for the diagnosis of coronary artery disease. Acarix AB (publ) was founded in 2009 and is headquartered in Malmö, Sweden.